Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access SEC filings for Agenus Inc (NASDAQ: AGEN), providing regulatory documentation essential for understanding this clinical-stage immunology company's financial position, operational developments, and material events. These filings offer official disclosure of information required by securities regulations.
As a publicly traded biotechnology company, Agenus files regular reports with the Securities and Exchange Commission including quarterly reports (10-Q), annual reports (10-K), and current reports (8-K) for material events. These documents provide detailed information about the company's clinical programs, financial condition, risk factors, and corporate governance.
Key filing types relevant to Agenus investors include 8-K filings announcing clinical trial results, partnership agreements, and significant corporate developments. The company's 10-K annual reports offer comprehensive overviews of pipeline programs, competitive landscape analysis, and detailed financial statements with auditor opinions.
Proxy statements (DEF 14A) disclose executive compensation, board composition, and shareholder voting matters. Registration statements accompany securities offerings, providing prospectus information for capital raises that fund ongoing research and development activities.
Monitoring Agenus SEC filings enables investors to access official company disclosures before or concurrent with public announcements, supporting informed investment decisions. This page provides organized access to AGEN's complete filing history with the SEC.
AGENUS INC reported an insider equity transaction by its Chairman and Chief Executive Officer, Garo H. Armen, who is also a director. On December 26, 2025, Dr. Armen received 4,942 shares of common stock as payment of his salary for the pay period ending that day, instead of cash. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, at a reference price of $3.31 per share, which was the closing price of the common stock on that date.
Following this transaction, Dr. Armen beneficially owned 307,343 shares of Agenus common stock directly. He also held shares indirectly, including amounts in his IRA accounts and interests in entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. reported that Chairman and Chief Executive Officer Garo H. Armen received 4,316 shares of common stock on 12/12/2025 as payment of his salary in stock, in lieu of cash, at his request and with Compensation Committee approval. The shares were valued at $3.79, the closing price of Agenus common stock on December 12, 2025, and are fully vested on the date of issuance under the company’s 2019 Equity Incentive plan. After this transaction, Dr. Armen directly holds 302,401 Agenus shares, in addition to indirect holdings through IRA accounts and a trust and partnership structure.
Agenus Inc. (AGEN) reported that Chairman and CEO Garo H. Armen received part of his compensation in stock instead of cash. On 11/14/2025, he was issued 3,769 shares of common stock as salary for the pay period ending that date, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. The shares were valued using the $4.34 closing price of Agenus common stock on 11/14/2025 and are fully vested on the date of issuance. Following this transaction, Dr. Armen beneficially owns 294,498 shares directly, with additional indirect holdings reported through IRA accounts and entities in which he has a pecuniary interest.
Agenus Inc. reported Q3 2025 results. Total revenues were
On the balance sheet, cash and cash equivalents were
Management disclosed that, despite post-quarter cash actions—including a
Agenus Inc. reported its quarterly results for the period ended September 30, 2025 and furnished the accompanying press release as Exhibit 99.1. The company submitted this information under Item 2.02 of Form 8-K.
The disclosure is designated as “furnished,” not “filed,” meaning it is not subject to Section 18 liabilities and is only incorporated by reference if expressly stated. Agenus’s common stock trades on the Nasdaq Global Market under the symbol AGEN.
Agenus Inc. (AGEN) reported an insider transaction: Chairman and CEO Garo H. Armen acquired 4,120 shares of common stock on 10/31/2025 at $3.97 per share. The shares were issued as salary paid in stock, fully vested upon issuance, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan.
After the transaction, Dr. Armen’s direct beneficial ownership was 290,729 shares. He also holds 31,298 shares indirectly through IRA accounts and 28,950 shares indirectly via a GRAT and a partnership, as noted in the filing.
Agenus (AGEN) reported an insider stock compensation event. Chairman and CEO Garo H. Armen received 4,216 shares of Common Stock on 10/17/2025 as salary paid in stock, in lieu of cash, under the Amended and Restated 2019 Equity Incentive plan. The grant was valued using the $3.88 closing price on 10/17/2025 and the shares were fully vested at issuance.
Following the transaction, Dr. Armen beneficially owns 286,609 shares directly, plus 31,298 shares indirectly held in IRA accounts and 28,950 shares indirectly via trust/partnership interests as described in the footnotes.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,951 shares of common stock as salary in lieu of cash, issued under the company's equity plan. The shares were issued at the closing price of
Agenus Inc. (AGEN) director Thomas L. Harrison received 5,780 shares of common stock on 10/01/2025 under the company's Board Compensation Election Policy, electing to take director fees in equity rather than cash. The shares were issued at an average price of $5.01, which the filer says is the average closing price for the quarter preceding issuance. After this transaction, Mr. Harrison beneficially owns 22,079 shares. The Form 4 was filed by an attorney-in-fact on 10/03/2025, and no derivative transactions are reported.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
